Our team and others have highlighted how such dysregulations exert protumoral effects, such as the metastatic dissemination of melanoma tumor cells via pro-invasive interactions with stromal fibroblasts [206], the transition between the proliferative and the invasive phenotype [207], immune escape [208], and the contribution to the resistance to BRAF [209] and immune checkpoint inhibitors [210]. The gene discussed is BRAF; the disease is melanoma.